Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
EDITORIAL
Chemotherapy in patients with lung cancer and interstitial lung disease
1
First Academic Department of Pneumonology, Interstitial Lung Diseases Unit, Hospital for Diseases of the Chest, “Sotiria”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Corresponding author
Demosthenes Bouros
First Academic Department of Pneumonology, Interstitial Lung Diseases Unit, Hospital for Diseases of the Chest, “Sotiria”, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 152 Messogion Ave., Athens 11527, Greece
First Academic Department of Pneumonology, Interstitial Lung Diseases Unit, Hospital for Diseases of the Chest, “Sotiria”, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 152 Messogion Ave., Athens 11527, Greece
Pneumon 2017;30(4):224-226
KEYWORDS
REFERENCES (32)
1.
Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 2004; 91:Suppl 2:S3-10.
2.
Archontogeorgis K, Steiropoulos P, Tzouvelekis A, Nena E, Bouros D. Lung cancer and interstitial lung diseases: a systematic review. Pulm Med 2012;2012:315918.
3.
Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013;22:265-72.
4.
Tzouvelekis A, Spagnolo P, Bonella F, et al. Patients with IPF and lung cancer: diagnosis and management. Lancet Respir Med 2017; pii: S2213-2600(17)30478-2.
5.
Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2017; 45:1-10.
6.
Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31:1039-49.
7.
Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage iv non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35:3484-515.
8.
Stahel R, Thatcher N, Früh M, et al; Panel members. 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010: small-cell lung cancer. Ann Oncol 2011;22:1973-80.
9.
Chen YJ, Chen LX, Han MX, Zhang TS, Zhou ZR, Zhong DS. The efficacy and safety of chemotherapy in patients with nonsmall cell lung cancer and interstitial lung disease: A PRISMACompliant Bayesian Meta-Analysis and Systematic Review. Medicine (Baltimore). 2015;94:e1451.
10.
Niwa H, Nakahara Y, Yokoba M, Mitsufuji H, Sasaki J, Masuda N. Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease. Mol Clin Oncol 2017;7:604-8.
11.
Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K, Homma S. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology 2010;15:88-92.
12.
Minegishi Y, Takenaka K, Mizutani H, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 2009;48:665-72.
13.
Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 2011;71:70-4.
14.
Kenmotsu H, Naito T, Kimura M, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 2011;6:1242-6.
15.
Watanabe N, Niho S, Kirita K, et al. Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother Pharmacol 2015;76:69-74.
16.
Kato M, Shukuya T, Takahashi F, et al. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer 2014;14:508.
17.
Minegishi Y, Kuribayashi H, Kitamura K, et al. The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias. J Thorac Oncol 2011;6:801-7.
18.
Togashi Y, Masago K, Handa T, et al. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer. Clin Lung Cancer 2012;13:304-11.
19.
Watanabe N, Taniguchi H, Kondoh Y, et al. Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis. Int J Clin Oncol 2014;19:260-5.
20.
Kudoh S, Kato H, Nishiwaki Y, et al; Japan Thoracic Radiology Group, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008;177:1348-57.
21.
Naito Y, Tsuchiya S, Ishihara S, et al. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease. Am J Clin Oncol 2008;31:340-4.
22.
Kojima Y, Okudela K, Matsumura M, et al. The pathological features of idiopathic interstitial pneumonia-associated pulmonary adenocarcinomas. Histopathology 2017;70:568-78.
23.
Choi MK, Hong JY, Chang W, et al. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. Cancer Chemother Pharmacol 2014;73:1217-25.
24.
Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017; 50(2):1700050. doi: 10.1183/13993003.00050-2017.
25.
Guyard A, Danel C, Théou-Anton N, et al. Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. Respir Res 2017;18:120.
26.
Enomoto Y, Inui N, Kato T, et al. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Lung Cancer 2016;96:63-7.
27.
Mercer PF, Woodcock HV, Eley JD, et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax 2016;71:701-11.
28.
Antoniou KM, Tomassetti S, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. Curr Opin Pulm Med 2015;21:626-33.
29.
Comer BS, Ba M, Singer CA, Gerthoffer WT. Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther 2015;147:91-110.
30.
Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ. The antifibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer 2016;16:176.
31.
Iwata T, Yoshida S, Fujiwara T, et al. Effect of perioperative pirfenidone treatment in lung cancer patients with idiopathic pulmonary fibrosis. Ann Thorac Surg 2016;102:1905-10.
32.
Otsubo K, Kishimoto J, Kenmotsu H, et al. Treatment rationale and design for J-SONIC: A randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis. Clin Lung Cancer 2018; 19:e5-e9.
Share
RELATED ARTICLE
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
